- In January 2024, Novo Nordisk completed the COMBINE 3 phase 3a trial, which assessed IcoSema, a once-weekly combination therapy consisting of basal insulin icodec and semaglutide. The results demonstrated that IcoSema effectively reduced HbA1c levels and showed comparable efficacy to daily insulin glargine U100 and insulin aspart. This innovation addresses key patient needs for more convenient and effective treatment options
- In September 2023, Novo Nordisk entered into a partnership aimed at enhancing human insulin production in South Africa to improve the accessibility of affordable insulin across the African continent. This initiative targets providing insulin to 4.1 million individuals living with Type 1 and Type 2 diabetes by 2026. This initiative addresses the challenges of insulin accessibility in underserved regions, particularly in Africa. By focusing on local production and affordable pricing, Novo Nordisk is not only expanding its footprint in emerging markets but also contributing to the global effort to make diabetes care more accessible
- In March 2023, Eli Lilly announced a significant price reduction of 70% for its most widely prescribed insulin products, alongside a cap on out-of-pocket costs for patients at USD 35 per month. Starting May 1, 2023, the list price of Insulin Lispro will be reduced to USD 25 per vial. This move by Eli Lilly is a pivotal step in increasing insulin affordability, particularly in regions where the rising cost of diabetes care has become a significant challenge. By reducing insulin prices and implementing cost caps, Eli Lilly is likely to improve patient access to essential insulin therapies, which could drive demand in both developed and emerging markets
- In August 2023, Novo Nordisk A/S and Inversago Pharma entered into an agreement under which Novo Nordisk will acquire Inversago for a total consideration of up to USD 1.075 billion in cash, contingent upon the achievement of specific development and commercial milestones. This acquisition by Novo Nordisk aligns with the company’s broader strategy to strengthen its portfolio in metabolic disorders, particularly obesity and diabetes, which are growing global health concerns
- In March 2023, Diabeloop, a leader in Automated Insulin Delivery technology, announced a strategic partnership with Novo Nordisk. This collaboration aims to integrate Diabeloop’s advanced self-learning algorithm, DBL-4pen, designed for Multiple Daily Injections (MDI) therapy, with Novo Nordisk’s innovative connected and reusable insulin pens, NovoPen 6 and NovoPen Echo Plus. This partnership marks a significant advancement in the development of next-generation insulin delivery systems, combining cutting-edge digital technology with traditional insulin delivery methods
